Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dianthus Therapeutics Inc.

21.87
+1.426.94%
Post-market: 21.870.00000.00%16:30 EDT
Volume:282.09K
Turnover:5.99M
Market Cap:702.58M
PE:-8.57
High:21.96
Open:20.78
Low:20.37
Close:20.45
Loading ...

Company Profile

Company Name:
Dianthus Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
78
Office Location:
7 Times Square,43rd Floor,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Directors

Name
Position
Jason Gardner
Director,President and Chief Executive Officer
Michael W. Bonney
Director,Chair of our Board
Alexis Borisy
Director
Alison F. Lawton
Director
Amy L. Ronneberg
Director
Anne McGeorge
Director
Blake Byers
Director
Bruce Booth
Director
David T. Scadden
Director
Jeffrey Albers
Director
Thomas O. Daniel
Director

Shareholders

Name
Position
Jason Gardner
Director,President and Chief Executive Officer
David Nichols
Chief Technical Officer
John C. Davis, Jr.
Head of Research and Development and Chief Medical Officer
Kristen Stants
Chief People Officer
Lisa Olson
Head of Research and Chief Scientific Officer
Stephen F. Mahoney
Chief Financial and Operating Officer and Treasurer
Zoran Zdraveski
Secretary and Chief Legal and Technology Operations Officer